Zobrazeno 1 - 10
of 122
pro vyhledávání: '"angiotensin-converting enzyme inhibitors (ACEi)"'
Publikováno v:
Heliyon, Vol 10, Iss 21, Pp e39423- (2024)
Objective: To report a case of drug-induced isolated angioedema secondary to the use of Entresto (Valsartan/Sacubitril). Case summary: A 75-year-old White man presented with swelling of the uvula with a normal tongue shape and gradual onset of speech
Externí odkaz:
https://doaj.org/article/33ddbb3056a442e6b83040fe52b71665
Autor:
JungMin Choi, So-Ryoung Lee, Eue-Keun Choi, Kyung-Yeon Lee, Hyo-Jeong Ahn, Soonil Kwon, Bongseong Kim, Kyung-Do Han, Seil Oh, Gregory Y. H. Lip
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 11 (2024)
BackgroundPatients with hypertension are at a high risk of atrial fibrillation (AF). Recent research has indicated the varying effects of antihypertensive medications on developing AF.ObjectivesWe investigated the relationship between different types
Externí odkaz:
https://doaj.org/article/74ddd2beb3fe4b50a73000ab47bc0a79
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-26 (2022)
Abstract Background Sacubitril/valsartan and angiotensin-converting enzyme inhibitor (ACEI)/angiotensin-receptor blocker (ARB) therapies were reported to affect glycaemic control and the development of diabetes mellitus (DM), but the findings are inc
Externí odkaz:
https://doaj.org/article/c3f5b061ec8e4bf796bd4c90720f65c5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Zhijie Liu, Ning Bian, Shaorong Wu, Yantao Cao, Yiting Su, Wenying Li, Hairui Li, Xianwu Lan, Can Jiang, Yiming Fan, Jun Guo, Dongdong Chen
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
AimsPermanent pacemaker implantation (PPI) combined with hypertension leads to a higher risk of new-onset atrial fibrillation (NOAF) for patients. Hence, it is essential to study how to reduce this risk. Currently, the effects of the two common anti-
Externí odkaz:
https://doaj.org/article/79155a65f8e447a4b573d65df246519f
Autor:
Mykola Khalangot, Nadiia Sheichenko, Vitaly Gurianov, Tamara Zakharchenko, Victor Kravchenko, Mykola Tronko
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
PurposeThe effect of renin-angiotensin-aldosterone system (RAAS) inhibitors in combination with COVID-19 and diabetes mellitus (DM) remains unknown. We assessed the risk of death in COVID-19 inpatients based on the presence or absence of DM, arterial
Externí odkaz:
https://doaj.org/article/b8107d0c85b045eb962754791fb144fc
Publikováno v:
Future Journal of Pharmaceutical Sciences, Vol 7, Iss 1, Pp 1-10 (2021)
Abstract Background Angiotensin-converting-enzyme-2, being the receptor for SARS-CoV-2, is increased in the use of RAAS inhibitors. Therefore, concerns have been raised over risks of SARS-CoV-2 infection and poor prognosis of COVID-19 in persons with
Externí odkaz:
https://doaj.org/article/bab377e61620414093d3976e43904733
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 15, Iss 3, Pp 416-423 (2019)
Headache is considered to be one of the main symptoms of arterial hypertension (HT). Complaints of headache are presented by many patients with HT: from 44% to 87%. It is obvious that the majority of complaints of headache in patients with HT is not
Externí odkaz:
https://doaj.org/article/7c9b1dde7cdf4859a1310de0cb83d394
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Muthuswamy Balasubramanyam
Publikováno v:
European Medical Journal Diabetes (2020)
As the COVID-19 outbreak continues to endanger global health and hamper the world economy, there are concerns and reconsiderations for medication taken by patients with cardiometabolic disorders as they are more vulnerable to COVID-19. While several
Externí odkaz:
https://doaj.org/article/b678a2b790dc476a90619b82180c450d